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Abstract
Hypertension is a major contributor to fatal/nonfatal cardiovascular diseases, and timely identification and appropriate man-
agement of factors affecting hypertension and its control are mandatory public health issues. By inducing neurohormonal 
alterations and metabolic impairment, sleep disorders have an impact on a variety of cardiovascular risk factors, including 
hypertension, and ultimately increase the risk of cardiovascular events. There is evidence that qualitative and quantitative 
sleep disorders are associated with resistant hypertension and with impaired circadian blood pressure variations. However, 
sleep disturbances are often unrecognized, or heterogeneity exists in their management by non-specialists in the field. This 
document by the Italian Society of Hypertension summarizes the updated evidence linking sleep disorders to hyperten-
sion and cardiovascular diseases, the major underlying mechanisms, and the possible management strategies. A simpli-
fied, evidence-based diagnostic and therapeutic algorithm for comorbid hypertension and common sleep disorders, namely 
obstructive sleep apnoea and insomnia, is proposed.
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1 Introduction
A proper sleep-wake cycle markedly influences a multi-
tude of neuroendocrine systems, all of which are deeply 
involved in cardiovascular and metabolic homeostasis [1]. 
Accordingly, qualitative and/or quantitative sleep disorders 
adversely affect the physiology of the hypothalamic–pitui-
tary–adrenal axis, the glycolipid metabolism and the cardio-
vascular system, thus exerting a considerable impact on the 
overall cardiometabolic risk [2].
Specifically, observational studies and experimental evi-
dence fully support the existence of a close link between 
sleep disorders and arterial hypertension, cardiovascular 
disease, diabetes mellitus and/or obesity [3]. Because of 
the burden that all these diseases represent for the national 
health system, the risks of workplace accidents and traffic 
collisions and, finally, the losses due to reduced productiv-
ity, sleep disorders and excessive daytime sleepiness exert 
a relevant economic and social impact that fully justifies 
their inclusion among public health issues. In this context, 
adequate knowledge of sleep disorders and related solutions 
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is essential for the clinician involved in the prevention and 
treatment of cardiovascular and metabolic diseases.
Among sleep disorders affecting blood pressure (BP), 
obstructive sleep apnoea (OSA) has been consistently asso-
ciated with increased risk of incident hypertension and 
treatment-resistant hypertension, as well as impaired noc-
turnal physiological BP reduction (“dipping”), and is now 
recognised as one of the modifiable aggravating factors of 
the global cardiovascular risk [4]. In fact, OSA events are 
accompanied by acute changes in cardiovascular parameters, 
such as large fluctuations in BP and heart rate, associated 
with long-term changes in fluid homeostasis, all of which 
increase the risk of fatal and non-fatal cardiovascular events 
[5]. Delaying sleep onset also increases the likelihood of 
hypertension, with an estimated risk of 300% (odds ratio 
3.27; 95% confidence interval 1.20–8.96). In women, sleep 
deprivation might represent a peculiar cause of vulnerability 
to hypertension and cardiovascular events [6, 7]. In addition, 
the expression of more than 700 genes involved in multiple 
functions, including metabolic control and redox status, is 
modified by sleep deprivation [4, 8]. In parallel, a U-shaped 
association between sleep duration and all-cause mortality 
as well as increased cardiovascular risk has been described 
[9–11].
On these bases, hypertension guidelines emphasise the 
importance of investigating the possible presence of sleep 
disorders in patients with resistant arterial hypertension and 
loss of physiological nocturnal BP dipping, as well as the 
need for a multidimensional approach of the problem that 
includes both lifestyle changes (diet, exercise, weight loss) 
and medications [4].
He triad of “correct and timely diagnosis”—“lifestyle 
changes”—“resetting of the correct sleep-wake cycle” is 
gradually becoming the pillar of a correct approach to the 
issue of sleep disorders in cardiovascular prevention. Thus, 
accurately collecting a history of possible sleep disorders 
is essential in the evaluation of the patient with hyperten-
sion and/or increased cardiovascular and/or metabolic risk 
[4]. Lifestyle interventions, including diet and exercise, are 
especially relevant when excess weight is believed to favour 
a disordered sleep [12–15]. Restoring the correct function 
of the melatonin system—e.g. through oral administration 
of prolonged release melatonin at adequate dosages—might 
contribute to sleep restoration and cardiometabolic protec-
tion. Melatonin, in fact, is a hormone whose low levels have 
been frequently associated with the development of arterial 
hypertension [16], and whose administration in insomnia is 
also indicated in adults with cardiovascular comorbidities 
[17].
The document that follows this brief premise is promoted 
by the Italian Society of Hypertension in order to provide a 
summary of the state of the art of cardiovascular and meta-
bolic implications of sleep disorders. The purpose of the 
document is to generate an updated and shared training and 
information tool, with the aim of standardising the approach 
of clinicians to the problem and optimising the multidimen-
sional management of the hypertensive patient.
2  Physiology and Pathology of Sleep
As Heraclitus of Ephesus wrote: “To those who are awake, 
there is one world in common, but of those who are asleep, 
each is withdrawn to a private world of his own.”, implying 
that the concept of sleep is an active process and is unique 
to each individual. Sleep is one of the most important behav-
ioural characteristics of humans and animals, which forces 
them to spend a significant proportion of life in a state where 
reactions to environmental stimuli are inhibited and during 
which important cognitive processes are developed.
Although there are still many aspects to be defined, in 
particular concerning the meaning and function of sleep, 
research in the neurophysiology field over the last 30 years 
has made it possible to clarify some fundamental concepts 
such as the sleep-wake cycle and circadian rhythms.
As anticipated, sleep is a reversible state of interruption 
of motor interactions with the environment and is present 
in many animal species, even in simple organisms such as 
yeast. It is divided into rapid eye movement (REM) sleep, 
contrasted with non-REM sleep, where this oculographic 
feature does not occur.
This descriptive definition is associated with the pres-
ence/absence of a series of physiological functions that char-
acterise REM and non-REM sleep. In the former, in addition 
to the known eye movements, there is a marked muscular 
atony of the antigravity muscles which spares the diaphragm. 
Non-REM sleep, which accounts for about 80% of total sleep 
time, is further divided into 4 categories, according to the 
first classification by Rechtschaffen and Kales, reduced to 3 
(N1, N2 and N3) in 2007 after a re-evaluation by the Ameri-
can Academy of Sleep Medicine [18, 19]. During non-REM 
sleep, the brain works in a low-consumption mode that is 
visible at the electroencephalographic level through slow 
and broad waves; heart rate, respiratory rate and BP decrease 
in absolute values and become less variable.
The alternation of REM and non-REM sleep occurs sev-
eral times (on average 4–5) during the night at intervals of 
about 90–120 min. Stage N3 of non-REM sleep is more 
prominent in the first part of sleep, while REM sleep is more 
pronounced in the second part.
The alternation of sleeping and waking is part of a more 
complex process called a circadian rhythm. The circadian 
rhythm is a broader concept that is defined with a fundamen-
tal characteristic: it is an endogenous process that can occur 
even independently from the variation of the environmental 
features. However, at the same time, it is a process that is 
 
able to adapt to environmental stimuli while maintaining its 
own periodicity.
The ability of a cell or complex organism to keep track 
of time is inherent in a series of molecular mechanisms, the 
discovery of which earned Jeffrey C. Hall, Michael Rosbash 
and Michael W. Young the Nobel Prize in 2017 thanks to a 
series of studies on Drosophila melanogaster.
The presence of such molecular mechanisms that can 
establish the circadian rhythm universally in the differ-
ent cells and tissues of an organism poses a risk of lack of 
synchronisation.
This risk is minimised by the presence of a hierarchi-
cal organisation of cells capable of maintaining a circadian 
rhythm, at the top of which is the suprachiasmatic nucleus 
(SCN) in the hypothalamus. The SCN is located in a strate-
gic area which is near the optic chiasm.
In this way it can receive optical stimuli from one of the 
most important external factors (Zeitgeber, from the Ger-
man, “time giver”), able to synchronise a biological clock, 
i.e. light.
The extraordinary ability of the SCN to coordinate the 
biological clock of an organism has been confirmed in 
experiments where, by dispersing the single SCN neurons in 
culture, the molecular rhythms of each neuron were observed 
which, however, were out of step with one another [20].
In the intact SCN nucleus, on the other hand, a precise 
coordination of the various neurons is observed through the 
synaptic terminations, which use various neurotransmitters, 
including gamma-aminobutyric acid (GABA), allowing a 
common and synchronised output.
The activity of the SCN nucleus characterises a wide vari-
ety of cells and tissues of our body, starting from the para-
ventricular nucleus (PVN) of the hypothalamus on which 
it exerts an inhibitory action by conditioning the activity 
of the endocrine system and the autonomic nervous sys-
tem with particular regard to the production of melatonin. 
Therefore, since the activity of SCN is dependent on light 
stimuli, an increase in SCN activity during exposure to light 
is effectively able to reduce the production of melatonin by 
the pineal gland [21].
Melatonin is a fundamental neurohormone for the syn-
chronisation of the biological clock. It is produced by the 
pineal gland during the night hours reaching maximum con-
centrations in the blood between 2:00 a.m. and 4:00 a.m. 
and then gradually decreasing as the morning approaches.
Neurones located in the brain stem are also involved in 
the circadian regulation of sympathetic and vagal activ-
ity and the relative modulation by the autonomic nervous 
system of the cardiovascular system between day and night 
[22].
Sleep disorders can be grouped according to different 
classifications, one of the most widely used is the Interna-
tional Classification of Sleep Disorders (ICSD), which is 
now in its third edition and produced by the American Acad-
emy of Sleep Medicine [23].
This classification divides sleep disorders into the fol-
lowing categories:
1) Insomnia
2) Sleep-related breathing disorders
3) Central disorders of hypersomnolence
4) Circadian rhythm sleep-wake disorders
5) Parasomnias
6) Sleep-related movement disorders.
The first group includes insomnia, which is defined as a 
disorder characterised by difficulty in falling asleep or stay-
ing asleep, or by nonrestorative sleep. This disorder affects 
the subjective feeling of well-being, even causing daytime 
psychic, cognitive and somatic alterations.
This is the most frequently reported sleep disorder in 
clinical practice and in the general population. It is fre-
quently associated with other disorders; in particular, the 
most well-known and described link in the scientific litera-
ture is undoubtedly with mental disorders. In particular, it 
has been shown that the presence of insomnia is capable of 
predicting the onset of a depressive episode, anxiety, alcohol 
abuse, or psychosis and represents a risk for the development 
of suicidal ideation and behaviour [24].
Insomnia is also associated with high cardiovascular mor-
bidity and mortality, particularly when accompanied by a 
short sleep duration (Fig. 1) [25]. One possible explanation 
of this could be the altered BP profile over 24 h of sleepless 
patients with reduced dipping and nocturnal hypertension 
[26].
The second group encompasses all respiratory disor-
ders that occur during sleep, the most prevalent being OSA 
syndrome (OSAS). OSAS is determined by a transient but 
repeated interruption of breathing during sleep. This phe-
nomenon causes a qualitative change in night-time rest, 
which may lead to symptoms during waking, such as exces-
sive daytime sleepiness and fatigue.
As previously seen, sleep induces a state of general mus-
cle relaxation, particularly in the REM stage. The loss of 
muscle tone can cause the upper airway walls (hypopharynx) 
to narrow and begin to vibrate, thus producing the well-
known snoring phenomenon. In extreme conditions, an 
actual collapse of the walls can occur, or even the complete 
airway obstruction. In this case our brain briefly interrupts 
sleep by awakening; this leads to the recovery of adequate 
muscle tone, stopping the apnoea phenomenon. Patients suf-
fering from OSA, however, may not be aware of the many 
awakenings associated with apnoea, because sometimes 
wakefulness and lighter sleep are not so intense or prolonged 
that the individual reaches a state of consciousness. At 
morning awakening, however, there may often be a feeling 
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of not having had a restful night’s sleep and symptoms such 
as excessive sleepiness, fatigue or headache—characteristic 
expressions of poor sleep quality—may also appear.
Numerous studies have demonstrated the association 
between hypertension and OSAS both from a pathophysi-
ological point of view, documenting transient pressure rises 
due to an increase in sympathetic tone during obstructive 
events, and from an epidemiological point of view (Fig. 1) 
[27].
In addition to obstructive apnoea, central apnoea is also 
frequently found in patients with cardiovascular diseases 
such as heart failure. During central apnoea there is no 
obstruction to the upper airways; instead, pauses in breath-
ing occur due to lack of inspiratory chest or abdominal 
movements. The causes of this disorder are manifold and 
may be found in the mechanism of respiratory control in 
the central nervous system (CNS). Respiratory stimulation 
to the major muscles involved in breathing, such as the dia-
phragm, depends on several stimuli, including nerve affer-
ents originating in chemoreceptors. Unstable breathing that 
predisposes to hyperventilation and drops in  PaCO2 below 
the apnoeic threshold results in a reduction in the output 
to the respiratory muscles and therefore in central apnoea.
Many of the respiratory sleep disorders result in daytime 
hypersomnia due to sleep disturbed by apnoea and other 
respiratory events. There are other sleep disorders that are 
characterised by daytime hypersomnia not secondary to sig-
nificant functional sleep disruptions.
This is the case with primary hypersomnias, which 
include narcolepsy—a pathology characterised by excessive 
daytime sleepiness, often experienced as recurrent involun-
tary sleep attacks, which occur during the day. It is caused by 
an inability of the brain to regulate the sleep-wake cycle in 
a physiological manner. In patients with narcolepsy, there is 
a rapid and atypical emergence of REM sleep, in the 15–20 
min that elapse after falling asleep, and an intrusion of REM 
sleep during the day. Narcolepsy affects on average 1 in 
2000 people (0.05% of the population) and is characterised, 
in addition to daytime sleepiness, by three key symptoms 
caused by the intrusion of REM sleep during wakefulness: 
cataplexy, a sudden, brief, reversible episode of muscle 
weakness that occurs in conjunction with emotional stimuli; 
sleep paralysis, an experience that occurs while sleeping, 
during which the subject suddenly feels unable to move or 
speak and hypnagogic or hypnopompic hallucinations—
vivid dreamlike experiences that occur on falling asleep or 
waking from sleep respectively.
The ICSD classification also includes circadian rhythm 
disorders that result from a lack of synchronisation between 
sleep-wake cycles and the schedules imposed by social 
needs, resulting in fatigue, poor work and school perfor-
mance and sleep disorders, particularly difficulty in falling 
asleep or waking up at the desired times.
Circadian rhythm disorders include: delayed sleep phase 
syndrome, in which subjects tend to fall asleep between 3:00 
a.m. and 6:00 a.m. and wake up between 12:00 p.m. and 3:00 
p.m.; advanced sleep phase disorder—in these subjects there 
is a tendency to fall asleep and wake up early compared to 
the conventional setting; jet-lag disorder, in subjects who 
travel across at least two different time zones; and shift work 
sleep disorder, frequent in workers with shifts that alternate 
between day and night.
Parasomnias represent a broad and heterogeneous group 
of sleep disorders that consist of anomalous and involuntary 
Fig. 1.  Major mechanisms 
of the association between 
sleep disorders with increased 
cardiovascular morbidity and 
mortality. See text for details. 
OSA obstructive sleep apnoea
 
behaviours during sleep, sometimes aimed at achieving a 
goal.
They are further divided into NREM sleep parasomnias, 
such as sleepwalking and night terrors, and REM sleep para-
somnias, such as REM sleep behaviour disorder.
The latter is characterised by the loss of physiological 
muscle paralysis during REM sleep. Therefore, during 
the episodes, patients present excessive motor activity, 
often characterised by abrupt behaviours (such as scream-
ing, punching and kicking), in relation to the content of their 
dreams.
This disease can be associated in 40% of cases with some 
neurodegenerative diseases, such as Parkinson’s disease, 
multisystem atrophy and some forms of dementia.
Finally, sleep movement disorders are characterised by 
the appearance of simple and repetitive movements that dis-
turb sleep and its onset. Restless legs syndrome (RLS) is 
common, and manifests itself with a feeling of restlessness 
in the lower limbs at rest, typically in the evening, which 
induces the subject to move his or her legs and to walk, 
compromising falling asleep and the continuity of sleep. It 
often comes with rhythmic movements of the limbs during 
sleep, which disturb sleep and are associated with micro-
awakenings as well as transient increases in heart rate and 
BP during sleep.
Given the impact of periodic movements to the lower 
limbs on night-time BP [28, 29], RLS has been associated 
with the development of cardiovascular diseases (Fig. 1) 
[28]. However, this report needs confirmation from subse-
quent longitudinal studies.
3  Sleep Disorders and Cardiovascular 
Diseases
For many years, the role of sleep in human pathophysiol-
ogy has been the subject of attention almost exclusively by 
psychologists and neuroscience experts, but in more recent 
times the concept of sleep as a restorative process in the 
wider sense has become more established, extending to the 
physiological functions of the whole body. The link between 
abnormal sleep duration and diseases had already been 
hypothesised by Hippocrates, who had observed that “Both 
sleep and insomnolency, when immoderate, are bad”. The 
pace of modern life has caused a significant change in sleep 
duration and quality compared to the past, with an increase 
in the proportion of people claiming to sleep less than 7 h 
a day in recent years (from 22% observed in 1977 to 29% 
in 2009) [30, 31]. In particular insomnia, which is the most 
prevalent sleep disorder, seen in about a third of the people 
in the general population in Europe [30], has been associated 
with a number of pathological conditions. Over time, evi-
dence has accumulated to support a significant relationship 
between sleep disorders and metabolic and cardiovascular 
diseases (Fig. 1) [31].
3.1  Sleep Duration and Cardiovascular Risk Factors
A short sleep duration (SSD), defined as < 6 or 7 h a day of 
sleep, is associated with a higher prevalence of obesity. The 
results of some longitudinal studies also seem to support 
a relationship between SSD and incident obesity, with an 
increase in risk of 55%; the correlation seems particularly 
evident when the duration of sleep falls below 4 h [31]. Case 
studies indicate that people with SSDs tend to have more 
snacks between meals, have more irregular eating habits, 
consume more calories and eat more fat. Even those who 
sleep too much, or “long sleepers” (LS), are more often 
obese and tend to consume more calories and less healthy 
food. The relationship between abnormalities in sleep dura-
tion and energy consumption is a more complex and less 
researched area, although the role of an alteration in the 
relationship between energy intake and calorie consumption 
in both SSD and LS subjects seems evident [31].
Abnormalities in sleep duration are also associated with a 
higher prevalence of diabetes mellitus. A meta-analysis that 
included more than 10,000 subjects showed a significant risk 
of developing diabetes in those who sleep less than 5–6 h or 
more than 8–9 h per night, with a relative risk of developing 
diabetes of 1.28 and 1.48, respectively, during an average 
follow-up of approximately 10 years [32].
Some studies have also reported a relationship between 
short sleep duration and arterial hypertension, but the data 
are quite heterogeneous. The most recent meta-analysis 
[33] appears to indicate a U-shaped relationship in cross-
sectional studies, with an increased risk of hypertension 
for both those with reduced sleep duration and those with 
increased sleep duration. In longitudinal studies, however, 
there is a significant relationship with arterial hypertension 
for subjects with short sleep duration but not for LS [33]. 
This relationship seems to be more evident in younger ages: 
a recent analysis of the available data showed an increase in 
the risk of arterial hypertension of 51% among adolescents 
with short sleep duration, in the absence of significant asso-
ciations with long sleep duration [34].
3.2  Sleep Duration and Overt Cardiovascular 
Disease
The association described so far between sleep duration and 
obesity, metabolic abnormalities and arterial hypertension 
is also a valid prerequisite for a relationship with overt car-
diovascular diseases, which has been described in various 
studies, although with a slight heterogeneity in the reported 
results. Among the most recent, a cross-sectional analysis 
carried out on 32,152 subjects within the National Health 
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and Nutrition examination Survey (NHANES) [35] showed 
a significant association between sleep duration and cardio-
vascular diseases, and in particular, in patients with short 
sleep duration, a higher prevalence of subjects with a clini-
cal history of cerebral stroke (odds ratio, OR 1.45; CI 95% 
1.23–1.70), and heart failure (OR 1.65; CI 95% 1.40–1.95) 
was observed, even after correction for several possible con-
founding factors. A long sleep duration was also associated 
with cardiovascular disease, and in particular with stroke (or 
1.81; CI 95% 1.37–2.34) and heart failure (OR 1.47; CI 95% 
1.08–1.97). The interpretation of the results of part of the 
available studies is limited by their cross-sectional nature, 
which does not allow a certain causal attribution between 
sleep duration and observed events. For longitudinal studies, 
a broad meta-analysis [36] including 15 studies and 474,684 
subjects analysed the relationship between sleep duration 
and long-term risk of cardiovascular events, with a follow-
up duration of 6.9–25 years). As regards the risk of stroke, 
the authors described an increased risk of stroke (fatal and 
non-fatal) in subjects with short sleep duration (relative risk, 
RR 1.48, CI 95% 1.22–1.80, p = 0.0001) and also in sub-
jects with long sleep duration (RR 1.65, CI 95% 1.45–1.87, 
p = 0.0001).
Similar conclusions were also found regarding the risk 
of coronary events (fatal and non-fatal), with a relative 
risk of 1.48 (CI 95% 1.22–1.80, p = 0.0001) for subjects 
with short sleep duration and 1.38 (CI 95% 1.15–1.66, 
p = 0.0005) for those who reported long sleep duration. 
The meta-analysis showed inconclusive results with regard 
to total cardiovascular events and cardiovascular mortal-
ity; this finding may in part be linked to a less precise 
definition of the events on which the analysis is based, but 
it could also be justified by the presence of confounding 
factors not considered in the multivariate model adopted 
in this study and which could have influenced other similar 
studies in literature as well. The analysis of data from the 
United Kingdom Biobank (500,000 healthy adult subjects) 
recently confirmed the increased risk of myocardial infarc-
tion in subjects with less than 6 h of sleep (20% increase 
in risk). It also showed a 34% increase in risk associated 
with sleeping longer than 9 h [37]. The results, in the same 
study, of the Mendelian randomisation analysis supported 
a causal link between short sleep duration and risk of acute 
myocardial infarction. Very little data is available regard-
ing the relationship between sleep duration and cardiovas-
cular events in patients with confirmed cardiovascular dis-
ease. Kim et al. recently analysed the relationship between 
sleep duration and risk of events in about three thousand 
patients with confirmed coronary artery disease included 
in the “Emory Cardiovascular Biobank” [9]. Short or 
long sleep duration has been associated with a significant 
increase in the risk of death from all causes during an 
average follow-up of 2.8 years. When the authors focused 
on mortality from cardiovascular causes, a significant rela-
tionship with short sleep duration but not with long sleep 
duration emerged, after correction for possible confound-
ing factors.
As for the relationship between sleep duration and atrial 
fibrillation, the data available in the literature are not con-
clusive, although some, but not all, case studies seem to 
suggest a U-shaped relationship, as for cerebrovascular 
and coronary events [38, 39].
In conclusion, epidemiological data, although hetero-
geneous, convincingly supports the presence of a relation-
ship between short sleep duration and risk of cardiovas-
cular events (Table 1); this relationship is also reasonably 
supported by the possible role of hormonal alterations 
associated with a reduced sleep duration (possible increase 
in cortisol levels, suppression of leptin levels and increase 
in ghrelin, reduction of melatonin levels, alterations in the 
endocannabinoid system), insulin resistance, disruption in 
eating behaviour that can lead to being overweight and 
obesity, release of proinflammatory cytokines [31]. The 
relationship with long sleep duration and risk of cardio-
vascular complications seems to be less well established. 
Indeed, many confounding factors may play a significant 
role in this relationship. Prospective studies with strict 
standardisation, with analysis of all possible confounding 
factors and quantitative evaluation of sleep duration may 
better define the relationship between sleep duration and 
cardiovascular events.
Table 1  Relationship between sleep duration, determinants of cardio-
vascular risk, and cardiovascular events
Upwards/downwards arrows indicate increased/decreased risk for the 
relative condition, while the equal sign indicates similar risk com-
pared with intermediate sleep duration. The same number of arrows 
indicates no difference in risk between short and long sleep duration. 
Question marks indicate controversial evidence. See text for details





Calories intake ↑ ↑
Energy expenditure ↓? ?
Obesity ↑↑ ↑
Arterial hypertension ↑ ↑ ?
Diabetes mellitus ↑ ↑↑
Atrial fibrillation ↑ ? ↑ ?
Stroke ↑ ↑↑
Heart failure ↑↑ ↑
Myocardial infarction ↑ ↑↑
Coronary events ↑↑ ↑
All cause death ↑ ↑
Cardiovascular death ↑ =
 
3.3  Qualitative Sleep Abnormalities 
and Cardiovascular Risk
Disturbances in the quality of sleep are a further element 
that, other than sleep duration, could exert a negative influ-
ence on the cardiovascular system (Fig. 1).
It is not easy to correctly classify the presence of qualita-
tive sleep abnormalities. In fact, for a correct diagnosis, it 
is often needed to undergo complex investigations, such as 
polysomnography, which are difficult to apply as a screen-
ing method in the general population. Moreover, it is not 
always possible to discriminate to what extent qualitative 
sleep abnormalities cause unfavourable effects on the car-
diovascular system regardless of their repercussions on the 
duration of the sleep itself.
Qualitative sleep disturbances may include frequent 
nocturnal awakenings which cause excessively fragmented 
sleep, respiratory sleep disorders, including OSA, and peri-
odic movements of the limbs in sleep, a feature of restless 
leg syndrome (Table 2).
One aspect toward which the scientific interest is con-
stantly growing is represented by circadian rhythm sleep 
disorders, which often affect shift workers who frequently 
switch between daytime and night-time shifts.
The presence of fragmented sleep, interrupted by 
frequent awakenings, regardless of their causes, has a 
negative effect on the cardiovascular system in that the 
structure of sleep, that is the temporal succession of the 
various phases of sleep, is altered. There is consistent sci-
entific background attributing a protective significance to 
REM (rapid eye movement) sleep duration in relation to 
cardiovascular disease. This includes data from the Cardi-
ovascular Health Study where it was observed a linear and 
inverse relationship between REM sleep duration and the 
risk of atrial fibrillation [40]. Sympathetic tone is high 
during REM sleep, suggesting that those with less REM 
sleep may be characterized by higher levels of vagal tone, 
which may favor AF appearance. However, lower odds 
of AF were reported among those with a longer dura-
tion of slow-wave sleep, which is typically characterized 
by greater cardiac vagal modulation. The cross-sectional 
nature of the available evidence, however, does not allow 
to clarify whether differences in sleep architecture were 
an effect (rather than a cause) of AF. Among the mecha-
nisms of damaging effect, an increase in sympathetic tone 
and a decrease in parasympathetic tone have been identi-
fied as factors that are also associated with high levels of 
nocturnal BP and reduced nocturnal BP drop. Although 
Table 2  Qualitative sleep disorders and cardiovascular risk
The arrows and the equal sign indicate the strength of the association (equal sign: no association; one, two, three, or four arrows: mild, moderate, 
strong, very strong association). See text for details





Insomnia Quantitative and qualitative sleep disorder characterized by 
difficulty falling asleep, frequent nocturnal interruption, early 
awakening, accompanied by daytime symptoms related to this 
condition
↑↑ ↑↑
Fragmented sleep Qualitative alteration of sleep characterized by frequent and brief 
awakenings
↑= ↑↑
Sleep disordered breathing A group of clinical conditions characterized by abnormal breath-
ing during sleep. They include: obstructive apnoeas, central 
apnoeas, hypoventilation and sleep-related hypoxemia
↑↑ ↑↑
Obstructive sleep apnoea Episodes of partial or complete closure of the upper airways dur-
ing sleep leading to respiratory interruption, desaturation and 
awakening. If accompanied by daytime symptoms, it is called 
“obstructive sleep apnoea syndrome”
↑↑↑↑ ↑↑↑
Periodic limb movements in sleep Repetitive contraction of the upper or lower limbs during sleep, 
which often lead to frequent awakenings and fragmented sleep
= =
Restless leg syndrome Motor restlessness, uncontrolled movements and contractions 
of the lower limbs that occurs in the phases of falling asleep, 
sleep and awakening. When conscious, the patient feels a 
sensation of discomfort in the legs, accompanied by the need 
to move them continuously
↑↑ ↑
Circadian rhythm sleep disorders Alterations caused by the desynchronization between the endog-
enous sleep–wake rhythms and the normal external light–dark 
cycle, from endogenous causes (delayed or advanced sleep 
phases) or exogenous (intermittent night shifts)
↑↑↑ ↑↑
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these are still preliminary observations, the results of 
some studies which have suggested a link between frag-
mented sleep, regardless of total duration, and the risk 
of developing arterial hypertension are important in this 
context [41].
Obstructive sleep apnoea (OSA), a disease affecting about 
49% of men and 23% of women living in Europe [42], is by 
far the most studied category of sleep disorders in relation to 
cardiovascular disease. Large-scale studies suggested a dose-
dependent link between the number of OSAs and the risk of 
developing arterial hypertension, which also increases for 
mild forms (between 5 and 15 apnoea-hypopnoea events per 
hour) [43]. In this context, there are interesting data support-
ing a link between OSA, atherogenic dyslipidaemia [44] and 
the onset of metabolic syndrome [45].
One of the main mechanisms that affect the high car-
diovascular risk in OSA is the so-called “hypoxic load”—a 
combined index of the frequency and extent of the episodes 
of oxygen desaturation during sleep, able to act as a trigger 
of endothelial dysfunction and systemic inflammation [46].
The potential causal link between OSA and cardiovascu-
lar events is supported by the results of prospective longi-
tudinal studies. In the Sleep heart Study, in subjects under 
70 years of age, OSA was an independent predictor of the 
5-year incidence of coronary events (HR 1.10), ischaemic 
stroke (HR 1.58) and congestive heart failure (HR 2.38) 
[47]. The potential protective effect of treating OSA in terms 
of reducing cardiovascular risk is currently unclear.
Several screening tools exist to aid in identification of 
OSA patients, with five being fairly easy to administer: 
Stop, STOP-BANG (SB) (Fig. 2, Box 1), Epworth Sleepi-
ness Scale (ESS) (Fig. 2, Box 2), the Berlin Questionnaire 
(BQ), and the 4-Variable screening tool (4-V) (Fig. 2, Box 3) 
[48–52]. The ESS is a simple and validated questionnaire for 
assessing subjective daytime sleepiness or sleep propensity 
in adults in the context of sleep disorders [50]. The BQ con-
sists of 3 categories (snoring and apnoea frequency, daytime 
symptoms, and BP) related to the risk of having OSA, with 
individuals being at high risk if there are 2 or more catego-
ries where the score is positive, and low risk if there is only 
1 or no categories where the score is positive [51]. The 4-V 
is an equation consisting of four variables including gender, 
BMI, BP, and self-reported snoring [52]. SB has the highest 
sensitivity (97.6%), followed by the BQ (87%), while the 
4-V ≥ 14 has the highest specificity (74.4%), followed by 
the ESS (67%). Recently, a weighted ESS scoring system 
was developed to improve the accuracy of the AHI predic-
tion, resulting in strong capability in predicting the patients 
without OSAS or with severe OSAS and improvement in 
screening the patients with simple snoring [53]. However, 
external validity and generalizability of the weighted ESS 
need further investigations.
Periodic limb movements in sleep (PLMS) are often found 
during nocturnal apnoea–hypopnoea episodes in subjects 
with OSA. These abnormalities may also occur isolated (pri-
mary PLMS) or within the context of other diseases, such as 
peripheral neuropathies, nephropathy or psychiatric disor-
ders (secondary PLMS). Subjects with PLMS typically have 
shorter phases of N3 sleep and REM sleep. Although this is 
sufficient to hypothesize a relationship between PLMS, arte-
rial hypertension and cardiovascular risk, current epidemio-
logical observations, in contrast to the initial observations, 
do not seem to support a relationship between PLMS and 
cardiovascular risk factors independently from the effect of 
the confounding factors [54].
However, in the analysis of the relationship between 
PLMS and cardiovascular risk, if the field of investigation 
is restricted to those with symptoms compatible with restless 
leg syndrome (RLS), characterised by the discomfort that 
appears in the legs during rest, it is possible to find evidence 
of a possible relationship between this condition and cardio-
vascular risk. In the Nurses’ Health Study, in fact, subjects 
who reported symptoms compatible with RLS appeared to 
be at increased risk of developing myocardial infarction (OR 
1.8) and death from ischaemic heart disease (OR 1.5) over 
time; this risk was even greater when considering subjects 
with duration of symptoms greater than at least 3 years [55]. 
In contrast, many other subsequent studies did not confirm 
this initial evidence, indicating the heterogeneity of the defi-
nition and classification of RLS, the methodologies adopted 
for diagnosis, and the concomitant impact on cardiovascular 
risk of conditions associated with secondary RLS such as 
diabetic neuropathy as possible explanations, which often 
were not adequately considered in the analysis of the results.
The category of qualitative sleep disorders includes 
the cardiovascular consequences related to shift working, 
a condition to which an ever-increasing number of work-
ers are exposed. It is estimated that around 18% of work-
ers in Europe carry out at least 25% of their work at night. 
Although some of the adverse effects on the cardiovascular 
system of shift workers are due to sleep deprivation, there 
are other potential mechanisms of harm that can be iden-
tified in the disturbance of the circadian rhythm of sleep 
and in the increased predisposition to unbalanced diets and 
unhealthy lifestyles [56].
In a meta-analysis that attempted to quantify the adverse 
effects of shift working on the cardiovascular system, it was 
observed that this condition increases the risk of cardiovas-
cular events, particularly coronary events, by 17%. Moreo-
ver, this risk would appear to increase cumulatively from 
the fifth year of shift working [57]. The potential impact of 
prolonged rest periods following night-time shift working 
and of the type of shift (clockwise, anti-clockwise) on qual-
ity of life, as well as on the cardiovascular risk associated 
 
with shift working, represents a subject of great interest for 
study in the scientific landscape of today.
In conclusion, the data available in the literature, sum-
marised in Table 2, support the existence of a significant 
relationship between qualitative sleep disturbances and con-
firmed cardiovascular disease.
4  Treatment for Sleep Disorders
In order to properly set up the treatment of sleep disor-
ders, especially when associated with arterial hypertension 
or other cardiovascular risk factors, a correct hypnologi-
cal diagnosis should be made based on proper gathering 
of medical history information, on physical examina-
tion and often on the performing of polysomnographic 
Fig. 2.  Major screening ques-
tionnaires for obstructive sleep 
apnoea. See text for details
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examination of the most suitable type for the specific sus-
pected diagnostic.
In addition to the general collection of patient data and 
the pharmacological history, the medical history should 
also be aimed at identifying sleep habits (sleep and wak-
ing schedule, number of awakenings during the night, day-
time sleeps, etc.), and the presence of specific symptoms for 
different sleep disorders (e.g. snoring, daytime sleepiness, 
morning headache, degree of feeling rested in the morning, 
involuntary movements in sleep, etc.).
The physical examination is mainly useful for identifying 
the signs associated with OSA, in particular obesity, mainly 
central, macroglossia, the conformation of the uvula, tonsils 
and palate, skeletal abnormalities of the upper and lower 
jaw, possible nasal obstruction which, although not a cause 
of the respiratory disorder, may complicate treatment man-
agement, in particular with positive pressure devices.
The cardiothoracic physical examination is essential for 
any signs of lung disease, baseline heart disease or skeletal 
spinal diseases such as kyphoscoliosis. For all non-respir-
atory sleep disorders, an in-depth neurological physical 
examination is also indicated.
Diagnostic investigations are usually required when spe-
cific symptoms and signs suggest the presence of a sleep 
apnoea, epilepsy with seizures during sleep, narcolepsy, 
periodic limb movements in sleep, or other disorders for 
which diagnosis is based on the identification of charac-
teristic polysomnographic findings. In other cases (such as 
psychophysiological insomnia, bad sleep habits, transient 
stress, disrupted sleep from work shifts), polysomnographic 
investigations are not always necessary. In some cases, a 
video recording may be associated with polysomnographic 
monitoring and in this case the examination is performed 
in the sleep lab. In the vast majority of cases, however, the 
tests carried out at home with portable polysomnographs are 
sufficient to establish a correct diagnosis particularly in the 
context of respiratory sleep disorders.
The therapeutic setting for sleep disorders is therefore 
closely linked to the specific diagnosis performed by the 
sleep medicine specialist. In this context, we will discuss in 
detail the treatment of the two sleep disorders most closely 
related to cardiovascular diseases and arterial hypertension: 
insomnia and OSA, also discussing the impact of these treat-
ments on BP levels.
4.1  Treatment of OSA
The treatment of choice for sleep respiratory disorders, in 
particular for OSA, is based essentially on the severity of 
the disorder, the general characteristics of the patient and 
the possible presence of comorbidities (Fig. 3).
Certainly, in the face of the presence of overweight/obe-
sity, the first step is to obtain weight loss, aiming to modify 
the lifestyle with an increase in daily physical activity, in 
addition to dietary changes.
It is also useful to avoid excessive consumption of alco-
hol in the evening and sedative drugs that can aggravate the 
respiratory sleep disorder.
The gold standard of treatment of OSA is still the use 
of continuous positive airway pressure (CPAP) or bilevel 
positive airway pressure (BIPAP) devices through nasal or 
oronasal masks, depending on the shape of the patient’s face.
These ventilation support devices provide positive air-
way pressure which allows the patency of the airways to be 
maintained during sleep. In order to be able to identify the 
specific therapeutic pressure for each patient capable of cor-
recting OSA and snoring, it is necessary to titrate the pres-
sure of the air delivered by the device by means of nocturnal 
adaptation polygraph.
In the case of positional sleep apnoea (i.e., occurring 
when the patient sleeps in supine decubitus) it may be useful 
to use supine position distractor devices, which essentially 
force the patient to adopt a lateral decubitus position during 
sleep.
In recent years, mandibular advancement devices (MAD) 
have been developed, which are worn during sleep and serve 
to fix the lower jaw slightly forward of the upper jaw, so that 
it does not tend to obstruct the airways during sleep.
There are also a number of surgical solutions for snoring 
and for apnoea, ranging from upper airway surgery to bari-
atric surgery in severely obese patients. The type of inter-
vention in the upper airways must however be evaluated by 
specialists experienced in sleep medicine after fibroscopic 
and functional investigations, in order to establish the cor-
rect surgical indication [58].
4.2  Treatment of Insomnia
First-line treatment for insomnia is cognitive-behavioural 
therapy, which should ideally be performed before hypnot-
ics are prescribed. Good sleep hygiene is one component 
of cognitive-behavioural therapy that is important whatever 
the cause and is often the only treatment that patients with 
mild problems need.
Cognitive-behavioural therapy for insomnia focuses on 
managing common thoughts, worries and behaviours that 
interfere with sleep (Fig. 4) [59].
General guidelines for the use of hypnotics aim to mini-
mise abuse, misuse and dependence.
All hypnotics (except ramelteon, low doses of doxepin 
and suvorexant) act on the benzodiazepine recognition 
site on the γ-aminobutyric receptor (GABA) and increase 
the inhibitory effects of γ-aminobutyric acid. Melatonin, 
which in Italy is registered as a drug in its 2 mg prolonged-
release formulation and has a specific first-line indication 
 
Fig. 3.  Diagnostic workup and 
treatment options for obstruc-
tive sleep apnoea. See text for 
details. OSA obstructive sleep 
apnoea, BDZ benzodiazepines, 
CPAP continuous positive 
airway pressure, BIPAP bilevel 
positive airway pressure, ASV 
adaptive servo ventilation, 
MAD mandibular advancement 
devices
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Fig. 4.  Diagnostic workup and 
treatment options for insom-
nia. See text for details. OSA 
obstructive sleep apnoea, BDZ 
benzodiazepines, ESS Epworth 
sleepiness scale, ISI insomnia 
severity index, DBAS-16 dys-
functional beliefs and attitudes 
about sleep
 
for insomnia in patients over 55 years of age, does not act 
on GABA receptors [60].
Hypnotics differ mainly in terms of elimination, half-life 
and principle of action. Some hypnotics (e.g., first-gener-
ation benzodiazepines) have greater chances of inducing 
residual sedation in the morning, especially after prolonged 
use and/or in the elderly, in which they may also increase the 
risk of falls, episodes of confusion and impaired cognitive 
performance.
In recent decades, selective hypnoinducers, so-called 
Z-drugs (such as zolpidem and zopiclone) have been devel-
oped, which can theoretically be taken even in conjunction 
with an infra-hypnic awakening provided that patients have 
the chance to sleep for at least 4 h after administration.
Hypnotics should be used with caution in patients with 
respiratory failure. In the elderly, any hypnotic, even at 
reduced doses, can cause restlessness, psychomotor agita-
tion, or exacerbation of states such as delirium and dementia.
Difficulties can be minimised by using the lowest effec-
tive dose for brief periods and gradually reducing the dose 
before stopping the drug.
It should also be recalled that both European guidelines 
and an Italian consensus indicate 2 mg prolonged-release 
melatonin as the first therapeutic choice in insomniac sub-
jects over the age of 55 years for up to 13 weeks [17, 60]. 
In addition to benzodiazepines and hypno-inducing drugs, 
there are also many other drugs not specifically indicated 
for insomnia that are used to induce and maintain sleep. 
Antihistamines such as doxorubicin and diphenhydramine 
can induce sleep. However, their efficacy is variable; moreo-
ver, these drugs can cause adverse effects such as confusion, 
urinary retention and possible systemic anticholinergic side 
effects, which are potentially serious in the elderly.
Antidepressants taken at low doses at bedtime (e.g. 5–20 
mg paroxetine, 50 mg trazodone, 75–200 mg trimipramine) 
may improve sleep. However, they should be used at low 
doses mainly when standard hypnotics are not tolerated 
(rare), or in high doses (antidepressants) when concomitant 
depression of mood is present.
Melatonin is a hormone that is secreted by the pineal 
gland (and is found naturally in some foods such as oats, 
almonds and corn, for example). Darkness stimulates secre-
tion, whereas light inhibits it. By binding melatonin recep-
tors in the suprachiasmatic nucleus, melatonin regulates the 
circadian rhythm and especially the sleep–wake cycle. Exog-
enous melatonin supplementation may be indicated in vari-
ous sleep disturbance conditions: jet lag, fragmented sleep 
or delayed sleep phase syndrome. Oral melatonin can be 
administered in different dosages and formulations depend-
ing on the condition we are treating (typically from 0.5 to 5 
mg before bedtime). The key element is the time of admin-
istration, which must be regular and chosen on the basis of 
the sleep disorder we are dealing with [61, 62]. The choice 
of the product to be taken is therefore key, since most of the 
available melatonin products are “over-the-counter” supple-
ments and sometimes the actual dosage of melatonin they 
contain is not well regulated.
In Italy there is only one product registered as a pro-
longed-release melatonin-based drug at a dose of 2 mg [17].
Treatment response can be evaluated with the readmin-
istration of questionnaires first collected at baseline for the 
assessment of insomnia severity (Insomnia Severity Index, 
ISI [63]) or sleep related beliefs and attitudes in insomnia 
(Dysfunctional Beliefs and Attitudes about Sleep short ver-
sion, DBAS-16 [64]) (Figs. 4, 5).
4.3  The Impact of the Treatment of Sleep Disorders 
on Blood Pressure
4.3.1  Obstructive Sleep Apnoea
Several studies have shown that treatment of OSA may allow 
a significant, albeit modest, reduction in BP. In particular, 
among the treatments specific to OSA, those that have been 
studied with regard to their effect on BP are CPAP devices 
and MAD. Recent meta-analyses indicate a significant but 
small reduction in BP values in OSA patients treated with 
CPAP [65–67], with more evident effects on patients with 
resistant hypertension and on overnight BP values. This is 
interesting because the role of nocturnal BP in the devel-
opment of cardiovascular diseases and its association with 
cardiovascular mortality and morbidity both in hypertensive 
patients and in the general population has been confirmed in 
several longitudinal and population studies [68]. In addition 
to higher baseline BP values, excessive daytime sleepiness 
and, in particular, increased treatment compliance are also 
associated with increased positive effects of CPAP treatment 
on BP [69, 70].
Oral devices are indicated for the treatment of mild to 
moderate OSA and their effect on BP values is promising, 
similar to that obtained with CPAP according to some stud-
ies. Recently, a meta-analysis [68] comprising data from 68 
randomised controlled studies comparing CPAP or MAD 
with passive or active treatment demonstrated that CPAP 
was associated with a mean reduction in BP of − 2.09 (CI 
95% − 2.78 to 1.40) mmHg for systolic pressure and − 1.92 
(CI 95% − 2.40 to 1.43) mmHg for diastolic pressure, while 
the corresponding values for MAD were − 1.27 (CI 95% 
− 2.34 to − 0.20) mmHg for systolic pressure and − 1.11 
(CI 95% − 1.82 to − 0.41) mmHg for diastolic pressure. 
A subgroup analysis showed that patients with higher BP 
values prior to treatment, patients < 60 years of age, and 
patients with higher hypoxic load were more likely to exhibit 
a more pronounced hypotensive effect in response to CPAP 
treatment.
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In terms of medical therapy, the most promising class of 
antihypertensive drugs capable of reducing both the sever-
ity of OSA and BP values are diuretics, particularly miner-
alocorticoid receptor antagonists, whose beneficial effects 
in this context are believed to derive from the reduction 
of peripheral oedema and volume overload [71], and the 
consequent reduction in the volume shift towards neck and 
central circulation which occurs when taking the supine 
position. In addition, other classes of antihypertensive drugs 
that showed convincing results have been tested. Eskandari 
Fig. 5.  Common questionnaires 
for detection and monitoring of 
insomnia. See text for details
 
et al. demonstrated that acetazolamide alone and in combi-
nation with CPAP reduced BP values, vascular rigidity and 
respiratory sleep disorders in patients with OSA and arterial 
hypertension [72]. Furthermore, in a French study, it was 
shown that, in patients with OSA, treatment with valsartan 
resulted in a greater reduction in BP than in CPAP alone, not 
only during the day but also at night [73].
4.3.2  Other Sleep Disorders
With regard to non-respiratory sleep disorders, a system-
atic review of the effects of prolonged sleep time on cardio-
metabolic risk factors [74] included only three small-scale 
studies in which BP was evaluated. None of these reported 
a significant positive effect. Conversely, a recent study that 
applied cognitive-behavioural therapy to prolong sleep in 
“short sleeper” adults and with prehypertension or stage 
one hypertension found significant reductions in BP with 
treatment [75]. There is little data on the beneficial effect 
of the treatment of insomnia and RLS on BP and it is often 
controversial.
Encouraging data on the possibility of reducing BP in 
sleep disorders are available for evening administration of 
prolonged-release melatonin 2 mg [76, 77].
In patients with moderate to severe RLS, rotigotine com-
pared to placebo appears to significantly reduce the acute 
spikes in BP associated with PLMS [78]. Finally, there are 
few studies on the BP effects of sleep disorder treatment in 
shift workers. A recent systematic Cochrane review of the 
pharmacological interventions for sleepiness and sleep dis-
orders caused by shift work highlighted the need for further 
and better-quality studies on the effects and costs of all phar-
macological agents that induce sleep or promote alertness 
in shift workers, both with and without a diagnosis of shift 
work sleep disorder [79].
5  Conclusions
This document by the Italian Society of Hypertension on 
qualitative and/or quantitative sleep disorders aimed to 
define a shared approach to a condition with a significant 
negative impact on overall cardiometabolic risk and related 
fatal/non-fatal events. At present, in fact, several open ques-
tions exist concerning the diagnosis, management and ther-
apy of hypertensive patients with sleep disorders. Although 
guidelines on arterial hypertension recommend investigating 
sleep quality/quantity as well as the presence of OSA, and 
specifically treating the latter in the hypertensive patient, 
several relevant aspects remain undetermined. These include 
the severity of respiratory disorder and BP threshold for 
indications for specific therapies; the most appropriate BP 
measurement tools in this context; the predictive factors of 
BP response, including the effects of antihypertensive drugs 
and lifestyle/weight interventions; and the management of 
insomnia in patients with obstructive apnoea [13, 27].
In addition to the evidence supporting the benefit of 
CPAP in terms of BP reduction in hypertensive patients 
with OSA, there is no data supporting that this measure 
reduces the risk of major fatal/nonfatal events, independ-
ent of apnoea severity, duration of follow-up, or treatment 
adherence [80]. At the same time, however, a certain degree 
of reversibility in the cardiovascular risk profile following 
treatment appears to be achievable [27]. It is likely that the 
magnitude of this benefit might depend on concomitant non-
modifiable factors, such as age or pre-existing irreversible 
organ damage, which would therefore affect the indications 
for specific treatments.
Consideration is also needed as to whether BP 
increases—both in terms of mean BP values and BP vari-
ability—that may potentially be observed during the use of 
CPAP depend on technical factors—such as air leaks from 
the mask or excessive positive pressure. These changes 
can be responsible for night-time awakening or represent a 
source of considerable discomfort for the patient, leading to 
discontinuation of treatment [27, 81].
Therefore, the appropriate management of patients with 
OSA and hypertension should be multifactorial, including: 
optimisation of type, number and doses of antihypertensive 
drugs; improvement of adherence to pharmacological and 
non-pharmacological treatments; implementation of lifestyle 
changes based on the overall cardiovascular risk; and identi-
fication and appropriate treatment of insomnia. Care to start 
treatment as early as possible in the clinical history of OSA, 
before structural cardiovascular changes might occur, also 
needs to be implemented.
Further research is needed to better clarify the relation-
ship between hypertension and sleep disorders, in the light 
of the many possible confounding elements. Similarly, 
dedicated studies that objectively assess the duration, qual-
ity, timing and regularity of sleep in relation to incident 
hypertension, identify the underlying genetic and molecular 
events, and define the role of more or less complex inter-
ventions (surgical procedures, use of intraoral devices, or 
selective nerve stimulation) in populations with different 
disease severity or baseline cardiovascular risk may clarify 
the significance of the observed associations. Pending these 
developments, it is mandatory to reduce the “time to diag-
nosis” of sleep disorders and relevant comorbidities in the 
hypertensive patient, especially if resistant to therapy and/
or at high cardiovascular risk, and to improve the available 
therapeutic strategies and adherence to them. In this context, 
it is worth it to investigate more thoroughly whether restor-
ing the melatoninergic system through prolonged-release 
melatonin at suitable doses [17] may represent, along with 
lifestyle changes, a widely applicable option. To date, the 
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triad “lifestyle changes + medications + possible device” 
stands as the only evidence-based approach.
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